EXHIBIT 99.1

               Express Scripts Restructures PlanetRx Relationship
           Customers Continue to Receive Online Prescription Services
                  Noncash Charge to be Taken in Second Quarter

     ST. LOUIS,  June 19, 2000 - Express Scripts,  Inc.  (Nasdaq:  ESRX),  today
announced that it has  restructured  its relationship  with  PlanetRx.com,  Inc.
Members of health plans using  Express  Scripts'  online  pharmacy  service will
continue to be able to access  PlanetRx.com for their  prescription  medications
through Express Scripts' and PlanetRx.com's websites.

     Under the restructured agreement, which is scheduled to take effect on July
5, 2000, Express Scripts will retain its ownership of approximately 10.4 million
common shares, or 9.9 percent, of PlanetRx.com,  and will receive a cash payment
of $8.0 million.  Approximately  $3.7 million of the fee  represents  the amount
earned through the second  quarter of 2000,  and the remainder  represents a fee
for the termination of the existing contract.  After this payment, no additional
cash payments will be paid under the  restructured  agreement.  Express  Scripts
will continue to utilize PlanetRx.com as its preferred online pharmacy.

     Express Scripts will record a pretax,  noncash asset  impairment  charge of
approximately  $145 million and a separate  related tax benefit of approximately
$55 million in the second  quarter of 2000 based on the current  market value of
PlanetRx.com.  The effect of these two  noncash  items will be to reduce  second
quarter  net income by  approximately  $90  million.  Express  Scripts is in the
process of finalizing  the actual  impairment  amount which will be reflected in
its second quarter financial statements.

     Excluding the noncash items, Express Scripts does not expect the changes in
the terms of the agreement to materially impact net income for 2000 or 2001. The
company is taking  steps to ensure that the  elimination  of  PlanetRx.com  cash
payments  beyond the third  quarter  will not result in a reduction  in reported
cash flow from operations or net income.  This will be accomplished  through the
early completion of numerous Internet  initiatives in the first half of the year
and the elimination of co-marketing expenses with PlanetRx.com.

     "Although we are restructuring our agreement with PlanetRx.com, much of the
intent of the original agreement is preserved in the restructured agreement. Our
first  priority is to  continue  to serve our clients and their  members who are
using the online pharmacy, and both companies are committed to provide members a
more convenient,  more complete online pharmacy  experience," stated George Paz,
senior vice president and chief financial officer of Express Scripts.

     "Express  Scripts  continues  to be  committed  to  building  our  Internet
strategy.  Our  web-enabled  operations  are  successfully  delivering  advanced
Internet   capabilities  that  narrow  the  information  gap  between  provider,
pharmaceutical  company, and plan sponsor in ways that reduce errors and improve
service quality," Paz stated. "The restructured agreement with PlanetRx.com will
not  have  any  material  adverse  effect  on  our  Internet  strategies.  We're
continuing to implement and develop  expanded  Internet  capabilities to benefit
our clients and their members."

     Under the terms of the October  1999  agreement  between  PlanetRx.com  and
Express  Scripts,  Express Scripts  obtained a 19.9% ownership in  PlanetRx.com.
PlanetRx.com  became the exclusive  Internet  pharmacy  serving Express Scripts'
plan members for five years,  with a potential  five-year  extension.  Under the
agreement,  PlanetRx.com  was to pay Express Scripts  annually fees in excess of
$11.6  million  for  access to its  membership  and $3 million  for the  further
development of Express Scripts' other Internet  capabilities for five years. The
company recorded a one-time  noncash gain of  approximately  $183 million in the
fourth quarter of 1999.

     Express Scripts provides  fully-integrated PBM services,  including network
claims processing,  mail-order pharmacy services,  benefit design  consultation,
drug utilization review, formulary management,  disease management,  medical and
drug data analysis  services,  medical  information  management  services (which
include   development  of  data   warehouses  to  combine   medical  claims  and
prescription  drug  claims,  disease  management  support  services  and outcome
assessments  through the  company's  Health  Management  Services  division  and
Practice Patterns Science,  Inc.  subsidiary),  and informed decision counseling
services through its Express Health Line SM division.  The company also provides
non-PBM  services,  including  infusion  therapy  services  through  its Express
Scripts  Infusion  Services  subsidiary and  distribution  services  through its
specialty  Distribution  subsidiary.  Express  Scripts is  headquartered  in St.
Louis,      Missouri.      More      information     can     be     found     at
http://www.express-scripts.com, which includes expanded investor information and
resources.

SAFE HARBOR STATEMENT

     This press release contains forward-looking statements,  including, but not
limited to, statements related to the Company's plans, objectives,  expectations
(financial and otherwise) or intentions. Actual results may differ significantly
from those projected or suggested in any  forward-looking  statements.  Specific
factors that may impact these forward-looking  statements include risks that the
steps the Company is taking to mitigate the  elimination  of cash  payments from
PlanetRx.com  will not be sufficient to fully offset the potential cash flow and
net  income  impact.  General  factors  that may  impact  these  forward-looking
statements   include  but  are  not  limited  to:  (i)  risks   associated  with
successfully  completing its Internet  strategy;  (ii) risks associated with the
consummation   and   financing  of   acquisitions,   including  the  ability  to
successfully  integrate the operations of acquired  businesses with our existing
operations, client retention issues, and risks inherent in the acquired entities
operations;  (iii) risks associated with obtaining  financing and capital;  (iv)
risks associated with our ability to manage growth;  (v) competition,  including
price  competition,  competition  in the  bidding and  proposal  process and our
ability to consummate contract  negotiations with prospective clients;  (vi) the
possible  termination of contracts with certain key clients or providers;  (vii)
the possible termination of contracts with certain pharmaceutical manufacturers,
changes  in  pricing,  discount,  rebate or other  practices  of  pharmaceutical
manufacturers;  (viii) adverse  results in litigation;  (ix) adverse  results in
regulatory  matters,  the adoption of adverse  legislation or regulations,  more
aggressive  enforcement of existing  legislation or regulations,  or a change in
the interpretation of existing  legislation or regulations;  (x) developments in
the healthcare industry,  including the impact of increases in healthcare costs,
changes in drug  utilization  patterns  and  introductions  of new  drugs;  (xi)
dependence on key members of management;  (xii) our  relationship  with New York
Life Insurance  Company,  which possesses voting control of the company;  (xiii)
other risks  described  from time to time in our filings with the Securities and
Exchange  Commission.  The company does not undertake any  obligation to release
publicly any revisions to such  forward-looking  statements to reflect events or
circumstances   after  the  date  hereof  or  to  reflect  the   occurrence   of
unanticipated events.